Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F23%3A00009542" target="_blank" >RIV/00023884:_____/23:00009542 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00133390 RIV/00216208:11130/23:10455101 RIV/00843989:_____/23:E0110120 RIV/00064203:_____/23:10455101 a 2 dalších

Výsledek na webu

<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full" target="_blank" >https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fonc.2022.1014455" target="_blank" >10.3389/fonc.2022.1014455</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

Popis výsledku v původním jazyce

The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients’ scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9–77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0–76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected.

Název v anglickém jazyce

Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

Popis výsledku anglicky

The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients’ scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9–77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0–76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Oncology

ISSN

2234-943X

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

000923996600001

EID výsledku v databázi Scopus

2-s2.0-85147275259